Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021

TheMotleyFool

0 0

Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021

Shares of Cassava Sciences (NASDAQ: SAVA) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

Like most small biotech stocks that have explosive gains, the move was due to good news from a clinical trial. On Feb. 2, the company issued a press release. The headline pretty much says it all: Cassava Sciences' Simufilam Improves Cognition and Behavior in Alzheimer's Disease in Interior Analysis of Open-label Study.

image source: Getty Images.

Source Fool.com

Like: 0

SAVA

Share